Cymabay
Newark, US · 4 known investors
Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas. The content served corresponds to Gilead rather than CymaBay.
Founders & leadership
HV
Harold Van Wart, Ph. D.Executive Officer, Director
CG
Carl Goldfischer, M.D.Director
PB
Pol BoudesExecutive Officer
KV
Kurt von EmsterDirector
HK
Hari Kumar, Ph.D.Director
CA
Charles A. McWherter, Ph. D.Executive Officer
LG
Louis G. Lange, M.D., Ph.D.Director
RJ
Robert J. WillsDirector
SS
Sujal ShahExecutive Officer
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$325KraisedAug 2015 · 2 investors · BiotechnologyRule 506(b)
▶$325KraisedAug 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harold Van Wart, Ph. D.Executive Officer, Director
- Carl Goldfischer, M.D.Director
- Pol BoudesExecutive Officer
- Kurt von EmsterDirector
- Hari Kumar, Ph.D.Director
- Charles A. McWherter, Ph. D.Executive Officer
- Louis G. Lange, M.D., Ph.D.Director
- Robert J. WillsDirector
- Sujal ShahExecutive Officer
- Offering amount
- $325K
- Amount sold
- $325K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.